bioRxivCancer BiologyPreprint
Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer
Hironobu YamashitaiD, Yuka Imamura Kawasawa, Lauren Shuman, Zongyu Zheng, Truc Tran, Vonn Walter, Joshua I. WarrickiD, Hikmat Al-Ahmadie, Matthew Kaag, Pak Kin Wong, Jay D. RamaniD, David J. DeGraffiD
Abstract
The discovery of bladder cancer transcriptional subtypes provides an opportunity to identify high risk patients, and tailor disease management. Recent studies suggest tumor heterogeneity contributes to \"plasticity\" of molecular subtype during progression and following treatment. Nonetheless, the transcriptional drivers of the aggressive basal-squamous subtype remain unidentified. As PPAR{gamma} has been repeatedly implicated in the luminal subtype of bladder cancer, we hypothesized inactivation of this transcriptional master regulator during progression results in increased expression of basal-squamous specific transcription factors (TFs) which act to drive aggressive behavior. We initiated a pharmacologic and RNA-seq-based screen to identify PPAR{gamma}-repressed, basal-squamous specific TFs. Hierarchical clustering of RNA-seq data following treatment of a panel of human bladder cancer cell lines with a PPAR{gamma} agonist identified a number of TFs regulated by PPAR{gamma} activation, several of which are implicated in urothelial and squamous differentiation. One PPAR{gamma}-repressed TF implicated in squamous differentiation identified is Transcription Factor Activating Protein 2 alpha (TFAP2A). We show TFAP2A and its paralog TFAP2C are overexpressed in basal-squamous bladder cancer and in squamous areas of cystectomy samples, and that overexpression is associated with increased lymph node metastasis and distant recurrence, respectively. Biochemical analysis confirmed the ability of PPAR{gamma} activation to repress TFAP2A, while PPAR{gamma} antagonist studies indicate the requirement of a functional receptor. In vivo tissue recombination studies show TFAP2A and TFAP2C promote tumor growth in line with the aggressive nature of basal-squamous bladder cancer. Our findings suggest PPAR{gamma} inactivation, as well as TFAP2A and TFAP2C overexpression cooperate with other TFs to promote the basal-squamous transition.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PPARG is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities.
L. Coutos-Thevenot, S. Beji, … I. BERNARD-PIERROT·bioRxiv·Dec 9, 2019
- Pparg drives luminal differentiation and luminal tumor formation in the urothelium
T. Tate, T. Xiang, … C. L. Mendelsohn·Nature CommunicationsPeer-reviewed·Oct 25, 2021
- Subtype-specific epigenomic landscape and 3D genome structure in bladder cancer
Tejaswi Iyyanki, Baozhen Zhang, … Feng Yue·Genome biologyPeer-reviewed·Apr 15, 2021
- Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks
H. Neyret-Kahn, J. Fontugne, … F. Radvanyi·bioRxiv·Jan 11, 2022
- The transcription factor AP-2β defines active enhancers conferring molecular apocrine cell identity in breast cancer
Ebtihal H Mustafa, Geraldine Laven‐Law, … Theresa E. Hickey·bioRxiv·Jul 5, 2025
- Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis
T. Tate, S. A. Plumber, … C. L. Mendelsohn·bioRxiv·Aug 19, 2023